- Home
- PTHL vs CLDI Comparison
PTHL vs CLDI Comparison
Compare PTHL & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- CLDI
- Stock Information
- Founded
- PTHL 1998
- CLDI 2014
- Country
- PTHL China
- CLDI United States
- Employees
- PTHL N/A
- CLDI N/A
- Industry
- PTHL
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTHL
- CLDI Health Care
- Exchange
- PTHL Nasdaq
- CLDI Nasdaq
- Market Cap
- PTHL 8.8M
- CLDI 8.7M
- IPO Year
- PTHL 2024
- CLDI N/A
- Fundamental
- Price
- PTHL $0.60
- CLDI $1.38
- Analyst Decision
- PTHL
- CLDI
- Analyst Count
- PTHL 0
- CLDI 0
- Target Price
- PTHL N/A
- CLDI N/A
- AVG Volume (30 Days)
- PTHL 122.3K
- CLDI 225.8K
- Earning Date
- PTHL 01-01-0001
- CLDI 11-07-2025
- Dividend Yield
- PTHL N/A
- CLDI N/A
- EPS Growth
- PTHL N/A
- CLDI N/A
- EPS
- PTHL N/A
- CLDI N/A
- Revenue
- PTHL $448,196.00
- CLDI N/A
- Revenue This Year
- PTHL N/A
- CLDI N/A
- Revenue Next Year
- PTHL N/A
- CLDI N/A
- P/E Ratio
- PTHL N/A
- CLDI N/A
- Revenue Growth
- PTHL N/A
- CLDI N/A
- 52 Week Low
- PTHL $0.47
- CLDI $1.10
- 52 Week High
- PTHL $32.00
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- PTHL 36.00
- CLDI 39.47
- Support Level
- PTHL $0.47
- CLDI $1.45
- Resistance Level
- PTHL $0.65
- CLDI $1.69
- Average True Range (ATR)
- PTHL 0.06
- CLDI 0.13
- MACD
- PTHL 0.04
- CLDI 0.01
- Stochastic Oscillator
- PTHL 63.46
- CLDI 46.61
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.